8-K: Kymera Reports Q3 2025 Results, Advances Key Programs

Kymera Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical pipeline, including progress for KT-621 and KT-579 programs.

Summary

• Net loss for the third quarter of 2025 was $82.2 million, compared to $62.5 million for the third quarter of 2024.
• Collaboration revenues decreased to $2.8 million for Q3 2025 from $3.7 million for Q3 2024.
• Research and development expenses increased to $74.1 million for Q3 2025 from $60.4 million for Q3 2024, primarily due to investment in the STAT6 program, platform, and discovery programs, and R&D organizational growth.
• General and administrative expenses increased to $17.3 million for Q3 2025 from $15.5 million for Q3 2024, mainly due to increased legal and professional service fees and personnel costs.
• As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents, and investments.
• The company expects its cash balance to provide a runway into the second half of 2028.
• Enrollment and dosing have been completed in the KT-621 BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data expected in December 2025.
• The KT-621 BROADEN2 Phase 2b trial in AD has been initiated.
• The KT-621 BREADTH Phase 2b trial in asthma is on track to initiate in the first quarter of 2026.
• IND-enabling studies for KT-579 (IRF5 degrader) have been completed, with a Phase 1 clinical trial expected to start in early 2026.
• Brian Adams, JD, was appointed as Chief Legal Officer and Corporate Secretary in September 2025.

Sentiment

Score: 7

Explanation: The financial results show an increased net loss and decreased collaboration revenue, which are negative. However, the company has a strong cash position and significant clinical and preclinical pipeline progress with multiple milestones expected soon, indicating strong operational execution and future potential. The increased expenses are tied to pipeline investment.

Positives

• Completed enrollment and dosing in the KT-621 BroADen Phase 1b trial in AD, with data anticipated in December 2025, marking a significant step as the first STAT6-directed agent in patients.
• Initiated the KT-621 BROADEN2 Phase 2b trial in AD and are on track to start the BREADTH Phase 2b asthma study in 1Q26, positioning for accelerated development and multiple registrational studies.
• Completed IND-enabling studies for KT-579, with Phase 1 clinical entry expected in early 2026, showcasing a novel oral approach to modulating IRF5.
• Strong cash, cash equivalents, and investments of $978.7 million as of September 30, 2025, providing a cash runway into the second half of 2028.
• Preclinical efficacy data for KT-579 demonstrated activity in additional models of lupus and rheumatoid arthritis, supporting its potential as a first-in-class mechanism.
• KT-621 Phase 1 healthy volunteer trial showed complete STAT6 degradation in blood and skin, reductions of multiple disease-relevant Type 2 biomarkers, and a safety profile undifferentiated from placebo.

Negatives

• Net loss increased to $82.2 million in Q3 2025 from $62.5 million in Q3 2024.
• Collaboration revenues decreased to $2.8 million in Q3 2025 from $3.7 million in Q3 2024.
• Research and development expenses increased by $13.7 million, reflecting higher investment in programs and organizational growth.
• General and administrative expenses increased by $1.8 million, driven by legal, professional service fees, and personnel costs.

Risks

• Cross-trial comparisons of KT-621 to dupilumab may not be reliable as no head-to-head trials have been conducted, and clinical data may not be directly comparable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations.
• Results from the Phase 1b KT-621 trial may differ from the Phase 1a KT-621 data.
• Preclinical and clinical data, including results from the Phase 1a trial of KT-621, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials.
• Uncertainties inherent in the initiation, timing, and design of future clinical trials.
• The availability and timing of data from ongoing and future clinical trials and the results of such trials are uncertain.
• The ability to successfully demonstrate the safety and efficacy of drug candidates is not guaranteed.
• The timing and outcome of planned interactions with and submissions to regulatory authorities are subject to uncertainty.
• The availability of funding sufficient for operating expenses and capital expenditure requirements is a continuous risk.
• The ability of each party to perform its obligations under the Kymera and Gilead exclusive option and license agreement is a factor.
• The unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development could occur.
• Whether Kymera will be able to fund development activities and achieve development goals, including those under the Kymera and Gilead collaboration, is uncertain.

Future Outlook

Kymera Therapeutics anticipates several important milestones through Q4 2025 and early 2026, including the release of KT-621 BroADen Phase 1b data in December 2025, the initiation of KT-621 BREADTH Phase 2b trial in asthma in 1Q26, and the start of KT-579 Phase 1 clinical trial in early 2026. The company expects its cash balance to provide a runway into the second half of 2028, supporting multiple clinical inflection points.

Management Comments

• "Our team has made impressive research, clinical, and regulatory progress this quarter to advance our first-in-class oral degrader medicines, and we look forward to several important milestones through the fourth quarter and early next year." Nello Mainolfi, PhD, Founder, President and CEO.
• "We've completed patient enrollment and dosing in the KT-621 BroADen Phase 1b trial in AD, marking a significant moment in the industry as the first STAT6-directed agent in patients, and we plan to share the full data set next month." Nello Mainolfi, PhD, Founder, President and CEO.
• "Additionally, we've initiated the KT-621 BROADEN2 Phase 2b trial in AD and are on track to start BREADTH, the Phase 2b asthma study, in the first quarter of 2026, positioning us on an accelerated development path to multiple registrational studies across areas of significant unmet need." Nello Mainolfi, PhD, Founder, President and CEO.
• "We were pleased to share additional preclinical efficacy data for KT-579 showcasing our novel oral approach to modulating IRF5, a key driver of multiple autoimmune disease pathologies. This program is on track for clinical entry in early 2026." Nello Mainolfi, PhD, Founder, President and CEO.
• "These important milestones across our industry leading oral immunology pipeline underscore our focus on delivering groundbreaking medicines to patients around the world." Nello Mainolfi, PhD, Founder, President and CEO.

Industry Context

Kymera is pioneering targeted protein degradation (TPD) for immunological diseases, a novel approach aiming to address targets inaccessible by conventional therapeutics. Their STAT6 degrader, KT-621, is noted as the first STAT6-directed drug in clinical evaluation, potentially transforming treatment for Type 2 inflammatory diseases affecting over 130 million patients. The IRF5 degrader, KT-579, also represents a first-in-class oral mechanism for autoimmune diseases. This positions Kymera at the forefront of developing new oral small molecule therapies in a competitive biopharmaceutical landscape.

Comparison to Industry Standards

• KT-621's Phase 1 healthy volunteer trial demonstrated complete STAT6 degradation and reductions of multiple disease-relevant Type 2 biomarkers, with a safety profile undifferentiated from placebo, suggesting a potentially favorable profile compared to existing therapies.
• The KT-621 BroADen Phase 1b trial aims to show a "dupilumab-like effect" on reducing Type 2 biomarkers and transcriptome in AD skin lesions, indicating a direct comparison to a leading biologic (Dupixent) in the AD market.
• In preclinical studies, KT-579 was equal or more efficacious than small molecule inhibitors and biologics currently marketed or in the clinic for lupus and rheumatoid arthritis, suggesting competitive or superior efficacy.
• The company explicitly cautions that cross-trial comparisons to dupilumab may not be reliable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through pipeline advancement and future clinical data readouts, but also increased net loss and R&D expenses. Strong cash runway provides stability.
• Patients: Potential for new, convenient, and highly effective oral therapies for a range of immunological and autoimmune diseases, including atopic dermatitis, asthma, lupus, and rheumatoid arthritis.
• Employees: Continued growth in research and development organization, as well as general and administrative functions, indicating job stability and expansion.
• Partners (Sanofi, Gilead Sciences): Ongoing collaboration activities and potential for future payments/milestones.

Next Steps

• Report data from KT-621 BroADen Phase 1b trial in AD patients in December 2025.
• Initiate KT-621 BREADTH Phase 2b trial in moderate to severe asthma patients in 1Q26.
• Advance KT-579 into Phase 1 clinical testing in early 2026.
• Continue IND-enabling studies for KT-485/SAR447971 with Sanofi, targeting clinical entry in 2026.
• Gilead Sciences to potentially exercise option for CDK2 molecular glue program.
• Topline data for KT-621 BROADEN2 Phase 2b trial in AD expected by mid-2027.

Key Dates

Recommendation

While the financial results show an increased net loss and decreased collaboration revenue, these are largely due to increased investment in a promising clinical pipeline. The company has a strong cash position providing a runway into late 2028, mitigating immediate funding concerns. Significant clinical milestones are anticipated in the near term (KT-621 data in December, KT-579 Phase 1 in early 2026), which could be major catalysts. However, the inherent risks of clinical development and the negative financial performance warrant a cautious "hold" until more definitive clinical data is released.

Keywords

Kymera Therapeutics, KYMR, Biotechnology, Targeted Protein Degradation, STAT6 degrader, KT-621, Atopic Dermatitis, Asthma, IRF5 degrader, KT-579, Immunological Diseases, Clinical Trials, Drug Development, Q3 2025 Financial Results, Biopharmaceutical, Autoimmune Diseases